🇺🇸United States
High Development Costs and Funding Shortfalls
2 verified sources
Definition
Biotech translational ventures face exorbitant costs in advancing research through clinical trials and regulatory stages, often requiring acquisition by larger firms for later phases. Without sufficient early-stage funding, projects stall and fail to reach market. The funding landscape pressures decisions on spin-outs, exacerbating cash burn in the expensive biomedical translation process.
Key Findings
- Financial Impact: $Hundreds of millions per project in unrecouped development costs
- Frequency: Ongoing throughout project lifecycle
- Root Cause: Expensive clinical trial phases combined with challenging funding access for early-stage biotech
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Biotechnology Research.
Affected Stakeholders
Spin-out Founders, Venture Capitalists, University TTO Staff
Action Plan
Run AI-powered research on this problem. Each action generates a detailed report with sources.
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Related Business Risks
Publish-or-Perish Conflicts with Patent Timing
$Reduced royalties over shortened patent life (estimable in millions for successful drugs)
Administrative Delays in Licensing Contracts
$Millions in lost future revenues per delayed project
Regulatory Approval Delays
$Millions per project in delayed market entry
Protocol Approval Delays Driving Trial Start-Up Time Drag
$55,716 per day Phase III trial delay; ~$390,000 per delayed week per site
Civil Money Penalties for ClinicalTrials.gov Non-Compliance in Biotech Trials
$10,000 per day per violation
High IRB/Ethics Committee Fees and Site Activation Delays
$1,000-$5,000+ per site IRB fee; $30,000-$200,000 total per site activation